Citadel Advisors’s BlackRock Capital Allocation Term Trust BCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.27M Buy
90,136
+72,687
+417% +$1.07M ﹤0.01% 7131
2025
Q4
$247K Buy
+17,449
New +$252K ﹤0.01% 10575
2025
Q2
Sell
-11,331
Closed -$163K 12560
2025
Q1
$163K Sell
11,331
-3,280
-22% -$50.1K ﹤0.01% 10738
2024
Q4
$221K Buy
+14,611
New +$235K ﹤0.01% 10266
2024
Q3
Sell
-34,255
Closed -$562K 14241
2024
Q2
$562K Buy
+34,255
New +$551K ﹤0.01% 7822

Other funds holding BCAT

Citadel Advisors's BCAT Position: Q1 2026 in Review

Citadel Advisors increased its BlackRock Capital Allocation Term Trust (BCAT) stake by 417% in Q1 2026, buying an estimated $1.07M and bringing the position to 90,136 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #7131.

Citadel Advisors first reported a position in BCAT in Q2 2024 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold BCAT as of Q1 2026.

  • Citadel Advisors held 90,136 shares of BlackRock Capital Allocation Term Trust worth $1.27M as of Q1 2026.
  • Citadel Advisors bought 72,687 BlackRock Capital Allocation Term Trust shares in Q1 2026, an estimated $1.07M.
  • BlackRock Capital Allocation Term Trust made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7131 holding.
  • Citadel Advisors first reported a position in BlackRock Capital Allocation Term Trust in Q2 2024 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held BlackRock Capital Allocation Term Trust as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.